At its worst, the doctrine condescends to patients, justifying denying funded access to a treatment on the basis it would be inequitable and unfair to others. This is an utterly false construct that pits patient against patient.
The mindset is that equitable access can only be achieved by denying everyone on the same basis
February 5, 2025 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Another day, and another example of our system's shortcomings
July 21, 2025 - - Latest News -
Companies have all the power in this process, if they choose to use it
July 21, 2025 - - Latest News -
Trump says countries will avoid tariffs if manufacturing returns to the US
July 21, 2025 - - Latest News -
Mesoblast updates investors on the succesful US launch of cell medicine
July 20, 2025 - - Australian Biotech -
Company refuses FDA request to halt distribution of gene therapy
July 20, 2025 - - Latest News -
Australian researcher awarded Gilead Sciences global grant to explore novel approach in breast cancer
July 18, 2025 - - Latest News -
The 'Dispatched' Week in Review Podcast - 17 July
July 17, 2025 - - Podcast